Table 3 |
|||||
|
Baseline predictors of ASAS20 response at three months of anti-TNF-α treatment |
|||||
|
Univariate analysis |
Multivariate analysis |
||||
|
OR (95% CI) |
P-value |
OR (95% CI) |
P-value |
||
|
|
|||||
|
Age (yr)†a |
0.982 (0.959 to 1.006) |
0.150 |
0.972 (0.947 to 0.998) |
0.035 |
|
|
Gender |
Female |
1 |
- |
- |
|
|
Male |
2.166 (1.185 to 3.958) |
0.012 |
3.151 (1.580 to 6.285) |
0.001 |
|
|
Duration of symptoms (yr)† |
1.001 (0.976 to 1.028) |
0.914 |
*** |
||
|
HLA-B27 |
Negative |
1 |
- |
- |
|
|
Positive |
0.779 (0.363 to 1.675) |
0.523 |
*** |
||
|
Peripheral arthritis |
Absent |
1 |
- |
- |
|
|
Present |
2.120 (0.876 to 5.129) |
0.096 |
** |
||
|
BASDAI (range 0 to 10)‡ |
0.946 (0.793 to 1.129) |
0.538 |
*** |
||
|
ASDAS‡ |
1.458 (0.992 to 2.144) |
0.055 |
* |
||
|
Physician's GDA (range 0 to 10)‡ |
1.122 (0.983 to 1.282) |
0.089 |
** |
||
|
Patient's GDA (range 0 to 10)‡a |
1.029 (0.882 to 1.201) |
0.714 |
** |
||
|
ESR (mm/h)‡a |
1.016 (1.000 to 1.032) |
0.049 |
1.023 (1.005 to 1.041) |
0.014 |
|
|
CRP (mg/l)‡ |
1.021 (1.003 to 1.040) |
0.025 |
* |
||
|
BASFI (range 0 to 10)‡ |
0.939 (0.816 to 1.081) |
0.382 |
*** |
||
|
Chest expansion (cm)‡a |
1.081 (0.948 to 1.233) |
0.243 |
** |
||
|
Modified Schober test (cm)‡ |
1.026 (0.861 to 1.224) |
0.773 |
*** |
||
|
Occiput to wall distance (cm)‡a |
0.981 (0.942 to 1.022) |
0.364 |
** |
||
|
Lateral lumbar flexion L (cm)‡ |
1.027 (0.965 to 1.092) |
0.402 |
*** |
||
|
Lateral lumbar flexion R (cm)‡ |
1.029 (0.968 to 1.094) |
0.352 |
*** |
||
|
TNF-α blocking agent |
ETA |
1 |
- |
- |
|
|
IFX |
2.045 (0.780 to 5.364) |
0.146 |
** |
||
|
ADA |
0.938 (0.476 to 1.846) |
0.852 |
** |
||
|
|
|||||
|
See Table 1 for definitions. OR refers to the risk of achieving ASAS20 response: † per year; ‡ per 1 grade or 1 point. a Significant difference (P < 0.05) between men and women at baseline. * CRP and ASDAS were not selected during forward conditional logistic regression due to the strong correlation with ESR (ESR and CRP: ρ = 0.669, P = 0.000; ESR and ASDAS: ρ = 0.412, P = 0.000). Although, higher CRP level (OR: 1.024, 95% CI: 1.004 to 1.044) and higher ASDAS level (OR: 1.728, 95% CI: 1.126 to 2.652) were also significant predictors of ASAS20 response at three months in the presence of age and gender. ** The variable was not selected during multivariate regression analysis (P ≥0.05). *** The variable was not tested in multivariate regression analysis because of a P-value > 0.3 in univariate regression analysis and no significant difference between men and women at baseline. |
|||||
|
Arends et al. Arthritis Research & Therapy 2011 13:R94 doi:10.1186/ar3369 |
|||||
